Image may be NSFW.
Clik here to view.
Clik here to view.
Noble starts Cynapsus at buy
Noble Financial Capital Markets has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and 12-month price target of $1.75. The stock closed at 38 cents on Monday. Cynapsus is...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Cynapsus PD data: couldn’t have wished for anything better
Anthony Giovinazzo “If I had asked for a gift, I couldn’t have wished for anything better,” says Anthony Giovinazzo, president and CEO of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH). He was...
View Article
More Pages to Explore .....
